Göhler et al. Final 14.03.2023

1	Performance of different nebulizers in clinical use for
2	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
3	
4	Short title: Technical characterisation of PIPAC nebulizers
5	
6	Daniel Göhler, DiplIng. ^{1,2} , Kathrin Oelschlägel, DiplIng ¹ , Mehdi Ouaissi, Prof, MD,
7	PhD ^{3,4} , Urs Giger-Pabst, Prof, MD ^{3,5}
8	
9	¹ Topas GmbH, Dresden, Germany
10	² Research Group Mechanical Process Engineering, Institute of Process Engineering and
11	Environmental Technology, Technische Universität Dresden, Dresden, Germany
12	³ EA4245 Transplantation, Immunology, Inflammation, Université de Tours, France
13	⁴ Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver
14	Transplant Surgery, University Hospital of Tours, France
15	⁵ Fliedner Fachhochschule, University of Applied Science Düsseldorf, Düsseldorf, Germany
16	
17	
18	Corresponding author:
19	Urs Giger-Pabst, MD
20	University of Applied Science
21	Fliedner Fachhochschule
22	Geschwister-Aufricht-Straße 9
23	40489 Düsseldorf, Germany
24	E-Mail: ursgiger@gmx.net
25	Phone: +49 163 729 44 07
26	
27	Key words
28 29	Pressurized Intraperitoneal Aerosol Chemotherapy, PIPAC, aerosol droplet size, gravimetry, Nebulizer, MCR-4 Topol [®] , HurriChem TM , QuattroJet

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 30 1

31 Author Contributions

32 Daniel Göhler and Urs Giger-Pabst: study design, experiments, data acquisition, data

- 33 interpretation and drafting of manuscript.
- 34 Kathrin Oelschlägel and Mehdi Ouaissi: critical revision for important intellectual content of
- the manuscript according to their field of research.

36 **Disclosure**

Strictly academic study supported by institutional funds. All authors have no conflicts ofinterest or financial ties to declare.

39 Data Availability Statement

40 All relevant data are within the manuscript. Raw data will be provided by the corresponding

41 author upon request.

42 Legal background

43 Purely technical analyses without the use of biological material or patients requiring no specific
44 legal authorization or ethics vote.

45 Acknowledgments

46 The authors thank Professor Marc Pocard, Hepato-Biliary-Pancreatic Gastrointestinal Surgery

47 and Liver Transplantation, Pitié Salpêtrière Hospital, AP-HP, F-75013 Paris, France, for

48 providing a HurriChem[™] (ThermaSolutions, White Bear Lake, MN, USA) nozzle.

I rights reserved. No reuse allowed without permiss *Göhler et al. Final 14.03.2023*

50 Abstract

Objective: Technical ex-vivo comparison of commercial nebulizer nozzles used for Pressurized
 Intraperitoneal Aerosol Chemotherapy (PIPAC).

53 *Methods:* The performance of four different commercial nebulizer nozzles (Nebulizer; 54 HurriChemTM; MCR-4 TOPOL[®]; QuattroJet) was analysed concerning: i) technical design and 55 principle of operation, ii) operational pressure as function of the liquid flow rate, iii) droplet 56 size distribution via laser diffraction spectrometry, iv) spray cone angle, spray cone form as 57 well as horizontal drug deposition by image-metric analyses and v) chemical resistance via 58 exposing to a cytostatic solution and chemical composition by means of spark optical emission 59 spectral analysis.

Results: The Nebulizer shows quasi an identical technical design and thus also a similar 60 performance (e.g., mass median droplet size of 29 µm) as the original PIPAC nozzles (MIP/ 61 CapnoPen). All other nozzles show more or less a performance deviation to the original PIPAC 62 nozzles. The HurriChemTM has a similar design and principle of operation as the Nebulizer, but 63 provides a finer aerosol (22 µm). The principle of operation of MCR-4 TOPOL[®] and QuattroJet 64 differ significantly from that of the original PIPAC nozzle technology. The MCR-4 TOPOL® 65 offers a hollow spray cone with significantly larger droplets (50 µm) than the original PIPAC 66 nozzles. The QuattroJet generates an aerosol (22 µm) similar to that of the HurriChemTM but 67 68 with improved spatial drug distribution.

69 *Conclusion:* The availability of new PIPAC nozzles is encouraging but can also have a negative 70 impact if their performance and efficacy is unknown. It is recommended that PIPAC nozzles 71 that deviate from the current standard should be subject to bioequivalence testing and 72 implementation in accordance with the IDEAL-D framework prior to routine clinical use.

Göhler et al. Final 14.03.2023

Introduction 1 74

75 More than a decade ago, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) was 76 introduced clinically as a new approach to deliver intraperitoneal chemotherapy to patients suffering from end-stage peritoneal surface malignancies. Using a high-pressure injector 77 78 connected to a specially designed PIPAC nozzle, liquid chemotherapeutic drugs are aerosolised 79 during laparoscopic surgery within the capnoperitoneum. This approach is expected to have a better spatial distribution pattern, greater depth of penetration, and higher drug concentration in 80 the tissue than conventional liquid intraperitoneal chemotherapy [1, 2]. Clinical data from phase 81 82 I/II and larger mono- and multicentre case series regarding safety, feasibility, and oncologic efficacy are encouraging. While the therapeutic role of PIPAC is still unclear [3], prospective 83 randomized PIPAC trials are underway and their results are eagerly awaited [4, 5]. 84

For over a decade, only the original PIPAC nozzle was available for clinical use, with more 85 than 18`000 documented clinical applications worldwide were projected by the end of 2022 [3]. 86 To ensure comparability of the outcome data, much efforts was spent to standardize PIPAC 87 therapy worldwide [6, 7]. But more recently, new nebulizer devices are also in clinical use. 88 While the technical and clinical performance data of the original PIPAC nozzle has been 89 extensively studied in pre- and clinical settings [3, 8, 9], no or only very limited comparative 90 91 data are available for the new PIPAC nozzles. Oncological surgeons around the world are now faced with the question of whether these newer nozzles are equivalent to the original nozzle 92 93 technology or perhaps even have technical/functional advantages with a potentially better oncological outcome? 94

On the basis of the methodological findings regarding the technical characterisation of the 95 original PIPAC nozzle [8], the current study deals with the comparative performance 96 characterisation of four commercial nebulizers as nowadays used for PIPAC. 97

98

Materials and Methods 99 2

2.1 **Examined PIPAC nozzles** 100

Four commercial single-substance PIPAC nozzles for intraperitoneal drug aerosolization were 101 102 examined, i.e.,

103 Nebulizer, Model 770-12, REGER Medizintechnik, Villingendorf, Germany (A),

I rights reserved. No reuse allowed without permiss Göhler et al. Final 14.03.2023

- HurriChemTM, ThermaSolutions, White Bear Lake, MN, United States of America (B),
- MCR-4 TOPOL[®], SKALA-Medica, Sobĕslav, Czech Republic (C),
- QuattroJet, Model 770-14, REGER Medizintechnik, Villingendorf, Germany (D).

After the experiments, all nozzles were cut-open longitudinally in the middle in a 180° angle
by means of a computerized numerical control milling machine to study their principles of
operation. In addition, also the dimensions of the nozzle outlet orifices were examined by light
microscopy (SMZ1500, Nikon, Tokyo, Japan).

111 2.2

2 Barometric characterisation of operational pressure as function of liquid flow rate

To characterise the operational pressure over the volumetric liquid flow rate, the nozzles were 112 connected via high-pressure hose lines with a high-pressure injector (ACCUTRON® HP-D. 113 114 MEDTRON AG, Saarbrücken, Germany) to push the test liquid (Glucosterile 5%, Fresenius Kabi GmbH, Germany) through the nozzles. The operational pressure induced by the liquid 115 116 flow rate was determined by means of a glycerine-filled bourdon gauge (MA7U-25, JRA Maschinenteile und Geräte GmbH, Reichenbach, Germany), which was implemented in the 117 high-pressure line. For the analyses, the volumetric liquid flow rate was increased stepwise 118 either by 0.1 ml/s (for nozzles A, B and D) or by 0.2 ml/s (for nozzle C) until the maximum 119 permitted pressure of 21 bar of the high-pressure injector was reached. For nozzle D, only the 120 axial nozzle was tested - the horizontal nozzles were sealed watertight. Analogous to [8], 121 measurement values were taken at steady state conditions of the aerosolization process and all 122 analyses were repeated three times. 123

124 2.3 Granulometric characterisation of droplet size distributions

The droplet size distributions of the aerosols generated from the test liquid (Glucosterile 5%, 125 Fresenius Kabi GmbH, Germany) were characterised by laser diffraction spectrometry 126 (PW180-C spray particle size analyser, Jinan K-Ring Technology Co., Ltd, Shandong, China) 127 over a size range of (0.57 - 780) µm. The outlets of the PIPAC nozzles were arranged via a 128 tripod in a distance of 5 mm perpendicular to the centre of the free-accessible red laser beam. 129 To characterise the aerosolization performance, all analyses were performed contemporaneous 130 with the barometric characterisation of the operational pressure for various liquid flow rates. 131 Analogous to [8], measurement values were taken at steady state conditions of the 132 aerosolization process and all analyses were repeated three times. 133

perpetuity. All rights reserved. No reuse allowed without permission.

Göhler et al. Final 14.03.2023

134 2.4 Image-metric characterisation of spray cone angles, form and horizontal drug 135 deposition areas

The spray cone angles, the form of the spray cones and the horizontal drug deposition area were characterised with different test liquids at nozzle-specific operation conditions as recommended by the manufacturers, i.e., at a volumetric liquid flow rate of 0.5 ml/s for the nozzles A, B, at 2.0 ml/s for nozzle C and 1.5 ml/s for nozzle D. The former two characteristics were evaluated on the base of a 5 wt.-% aqueous glucose solution (Glucosterile 5%, Fresenius Kabi GmbH, Germany), while the latter characteristic was assessed by operating the nozzles with undiluted royal blue ink (Pelikan Tinte 4001[®], Hannover, Germany).

For the spray cone angle analyses, the nozzles were fixed on a tripod and vertically aligned.
Photographic images were taken with a camera that was perpendicular positioned to the nozzle direction. The images were in-silico processed by overlaying with a digital 360° full-circle protractor for determining the spray cone angles.

The form of the spray cones was visualized by means of a line laser (GCL 2-15, Robert Bosch
Power Tools GmbH, Leinfelden-Echterdingen, Germany) positioned in distance of 60 mm from
the nozzle orifice at right angle into the spray cone. Fully evaluated spray cone forms were
finally documented photographically.

The horizontal drug deposition on a level-aligned blotting paper was examined by operating the vertically aligned nozzles with a distance of 60 mm between the blotting paper and the nozzle orifice. The blotting paper was exposed for 3 s to the fully-developed spray jet. To achieve this, a mechanical diaphragm was placed in front of the spray jet. The diaphragm was opened automatically within 0.1 s, when the aerosol jet showed steady state nebulisation condition.

156 2.5 Assessing of chemical resistance and chemical composition

To assess the chemical resistance of the nozzle material against chemotherapeutic drugs, the 157 nozzles were at first exposed to a cytostatic solution for 12 hours and afterwards stored in the 158 dark at room temperature for 12 days within petri dishes. The chosen cytostatic solution was 159 prepared in accordance to the mixture of high pressure/high dose PIPAC (HP/HD-PIPAC) [10], 160 161 i.e., 6 mg of doxorubicin (Accord 2 mg/ml, Accord Healthcare GmbH, Munich, Germany) was admixed with 50 ml of a 0.9 wt.-% aqueous sodium chloride solution (Ecolav[®] 100, B. Braun, 162 Melsungen, Germany). Finally, the nozzles were milled open in a laminar flow workbench and 163 macroscopic changes were documented photographically. 164

Perpetuity. All rights reserved. No reuse allowed without permission. *Göhler et al. Final 14.03.2023*

- 165 Moreover, the chemical composition of the nozzles pipes was characterised for the elements C,
- 166 Si, Mn, P, S, Cr, Ni, Mo, Cu, W and N by means of spark optical emission spectral analysis
- 167 (SPECTROMAXx, SPECTRO Analytical Instruments GmbH, Kleve, Germany) via an
- accredited laboratory (WS Material Service GmbH, Essen, Germany).
- 169

170 **3 Results**

171 3.1 Technical design and principle of operation

The 90° sectional views of the head regions in Figure 1 show technical destails of the examinednozzles.



Figure 1: 90° sectional views of the head regions of the nozzles. Legend: O = outlet orifice; H = nozzle
head; I = bar inlay with distal transverse borehole; M = double metal grid; N = fixed needle; S = shaft;
T = twist body.

Externally, all nozzles consist of a stainless steel shaft (S) with a more or less pronounced nozzle
head (H) on the lower part and a Luer lock thread on the upper part (not shown in Figure 1).
The Luer lock threads serve for the connection of the nozzles with high-pressure injectors via
high-pressure hose lines. Internally, the nozzles show partly considerable differences.

perpetuity. All rights reserved. No reuse allowed without permission. *Göhler et al. Final 14.03.2023*

- 182 Interestingly, nozzle A and B are quasi identical in construction and their principle of operation,
- 183 while the nozzles C and D differ significantly from them and from each other.

In the case of the nozzles A, B and D, the liquid drug is supplied internally from the Luer lock connector to the nozzle head via an annular gap between the outer shaft (S) and a bar inlay with distal transverse borehole (I). In contrast, the internal liquid drug supply of nozzle C occurs directly via the hollow cavity of the shaft (S). Moreover, nozzle C is equipped with a double metal grid (M) with two different mesh sizes that serve as particle filter.

- bodies (i.e., with one axial and three lateral twist bodies in 120° arrangement) to improve the

While the nozzles A and B contain one twist body (T), nozzle D is equipped with four twist

- 191 spatial drug distribution within the abdominal cavity. The twist bodies (T) of the nozzles A, B
- and D contain longitudinally superfically milled grooves at 180° intervals. As the liquid drug
- 193 flow rate passes along the twist bodies (T) they were set into rotation that improves the
- 194 aerosolisation prior leaving the nozzle via the outlet orifice (O). In the case of nozzle C, the
- 195 twist body is replaced by an fixed metal needle (N). This needle contains also laterally located,
- twist body is replaced by an fixed metal needle (N). This needle contains also laterally located,
- spirally milled axial grooves that induce a whirlwind effect for aerosolisation when passed by
- 197 the liquid flow before leaving the nozzle via the outlet orifice (O).
- Light microscopic images of the oulet orifices (O) with determined orifice diameters of theexamined nozzles are shown in Figure 2.



200

189



203 3.2 Operational parameters based on barometric and granulometric analyses

Figure 3 a depicts at first the determined operational pressure over the liquid flow rate of the examined nozzles, while in Figure 3 b the mass median diameter of the of the droplet size distribution over the operational pressure is given. To avoid artefacts due clouding of the optics

Göhler et al. Final 14.03.2023

207 of the laser diffraction spectrometer, the lateral nozzles of nozzle D (QuattroJet) were taped off for the granulometric analyses and a flow rate of 0.5 ml/s was chosen (manufacturer-208 209 recommended flow rate of 1.5 ml/s) Note that the shown data are determined at steady state conditions of the aerosolization process analogous to [8]. 210

211 It can be observed in Figure 3 a that the determined operational pressure data for all examined nozzles fit well with the fluid dynamic theory, i.e., the dynamic pressure (or the dynamic 212 pressure drop) of an incompressible fluid increases with the fluid velocity by the power of two. 213 According to the equation of continuity, the fluid velocity of an incompressible fluid is in turn 214 directly proportional to the volumetric liquid flow rate. The nozzles A, B and D show a similar 215 performance regarding operational pressure and liquid flow rate, while nozzle C (MCR-4 216 TOPOL[®]) has a significantly lower pressure drop and thus a considerable higher volumetric 217 liquid flow rate at a specific operational pressure. 218

Beside the whole operational spectrum, also the manufacturer-recommended operational 219 conditions were separately examined, i.e., at a volumetric liquid flow rate of 0.5 ml/s for nozzle 220 A (Nebulizer), nozzle B (HurriChemTM), (1.3 - 2.0) ml/s for nozzle C (MCR-4 TOPOL[®]) and 221 1.5 ml/s for nozzle D (QuattroJet). Under these preconditions nozzle C showed with (18 - 26) s 222 the shortest initiation time to reach the corresponding steady state pressure of (7.4 - 18.1) bar, 223 followed by nozzle A with 52 s (15.7 bar) and nozzle D with 94 s (16.0 bar). Note that with 224 taped-off lateral nozzles, nozzle D shows a higher operational pressure of 19.3 bar (as shown 225 in Figure 3). 226

All rights reserved. No reuse allowed without permission.





Figure 3: Operational pressure as function of the liquid flow rate from barometric analyses (a), mass median diameter as function of the operational pressure from granulometric analyses (b) and volumeweighted distributions density (c) and cumulative distribution (d) of droplets at certain manufacturerrecommended operational condition; black cycles/ellipses indicate manufacturer-recommended operation condition.

227

Figure 3 b shows that the mass median diameter of the generated droplet aerosols depends for each nozzle significantly on the operational pressure. With increasing operational pressure, the mass median diameter decreases. For operational pressures of ≤ 4 bar, quasi no significant difference between the different nozzles can be observed. This is attributed to a non-fully developed aerosolization of the supplied liquid. For operation pressures of ≥ 5 bar stable aerosol

l rights reserved. No reuse allowed without permiss *Göhler et al. Final 14.03.2023*

238 generation is reached and differences between the nozzles can be observed. For operational

239 pressures \geq 5 bar, nozzle C (MCR-4 TOPOL[®]) shows the coarsest mass median diameters,

240 followed by nozzle A (Nebulizer). The finest mass median diameters were determined for

241 nozzle B (HurriChemTM) and D (QuattroJet).

This ranking can also be deduced by the volume-weighted droplet size distributions of the aerosols as generated by the nozzles at the manufacturer-recommended operation conditions (Figure 3 c, Figure 3 d). Moreover, it can be observed in Figure 3 c and Figure 3 d, that each aerosol has a polydisperse and bimodal droplet size distribution.

246 3.3 Operational parameters based on image-metric analyses

247 Figure 4 shows photographic images for the spray cone angle (upper panel), the spray cone

form (mid panel) and the horizontal drug deposition area (lower panel) of each examined nozzle

as determined at manufacturer-recommended operational conditions.



Göhler et al. Final 14.03.2023

251 Figure 4: Photographic images of spray cone angle (upper panel), of spray cone form (middle panel) 252 and horizontal drug deposition area (lower panel, scale in cm).

According to the upper panel of Figure 4, the widest single spray cone angle was determined 253 with 79° for nozzle C (MCR-4 TOPOL[®]), followed with 72° for nozzle A (Nebulizer) and with 254 71° for nozzle B (HurriChemTM). Nozzle D (QuattroJet) shows with 67° the smallest single 255 spray cone angel, but it has to keep in mind that nozzle D contains in contrast to the other 256 nozzles of four spray cones. Moreover, it can be observed from the middle panel of Figure 4 257 that nozzle A (Nebulizer), nozzle B (HurriChemTM) and nozzle D (QuattroJet) generate a full 258 spray cone, whereas nozzle C (MCR-4 TOPOL[®]) produces a hollow spray cone. The full spray 259 cones of the nozzles A, B and C lead also to complete filled circular areas of horizontal drug 260 261 deposition beneath the nozzles as shown in the lower panel of Figure 4. In the case of the nozzles A and B, a circular deposition area of approx. 38.5 cm² (outer diameter of approx. 7 cm) was 262 263 determined. The lateral outlets of nozzle D showed beside the axial circle (outer diameter of 264 approx. 7 cm) also 3 additional deposition areas of (13×20) cm that cumulates to an overall horizontal deposition area of approx. 679 cm². 265

3.5 Chemical resistance and chemical composition 266

Photographic images of the nozzle parts after the exposure to the cytostatic solution are shown 267 in Figure 5. 268



269



Figure 5 shows that in the case of nozzle C (MCR-4 TOPOL[®]) the exposure to the cytostatic 271 solution led to the formation of iron oxide. These are particularly pronounced on the fine-mesh 272 273 particle filter, the nozzle needle and the nozzle head housing. No changes were observed for the nozzles A, B and D either visually or by light microscopic analyses. 274

275 The nozzles A, B and D fulfil all requirements according to EN 10088-3:2014 [11] on the 276 chemical composition of stainless steel 1.4301 that is typically used for surgical instruments.

Göhler et al. Final 14.03.2023

277 Beside a twelve times higher quantity of sulphur (0.012 wt.-% vs. 0.001wt.-%), also quantities

of molybdenum (0.183 wt.-%), copper (0.220 wt.-%) and tungsten (0.134wt.-%) were 278

- identified by spark optical emission spectrometry for nozzle C (MCR-4 TOPOL[®]). 279
- 280

4 Discussion 281

Due to the current lack of knowledge, four clinically-operated nebulising nozzles for PIPAC 282 were comparatively tested regarding their performance. The most important determined 283 technical characteristics of these nozzles are summarised in Table 1. 284

Table 1: Overview on technical and functional characteristics of the examined nozzles; * = 285 manufacturer-recommended operational conditions. 286

parameter	unit	A (Nebulizer)	B (HurriChem TM)	C (MCR-4 TOPOL®)	D (QuattroJet)
*liquid flow rate (*QL)	ml/s	0.5	0.5	1.3 - 2.0	1.5
operational pressure for $*Q_L$	bar	15.7	14.9	7.4 - 18.1	16.0
pressure initiation time for $*Q_L$	s	52	100	18 - 26	94
nozzle orifice diameter	μm	200	190	370	170
mass median diameter for 15 bar	μm	28.95	20.99	52.17	24.18
max. spray angle for *QL	o	≈ 72	≈ 71	≈ 79	≈ 67
number of nozzles	-	$1 \times axial$	$1 \times axial$	1 imesaxial	$1 \times axial, 3 \times lateral$
kind of spray cone	-	full cone	full cone	hollow cone	full cone
drug deposition area for *QL	cm ²	≈ 38.5	≈ 38.5	≈ 66	≈ 679

²⁸⁷

Nozzle A (Nebulizer) shows after an initiation time of 52 s an operational pressure of 15.7 bar 288 at the manufacturer-recommended operational liquid flow rate of 0.5 ml/s. Thereby, a full spray 289 jet cone (71°) composed of droplets with a mass median diameter of 29 µm is formed. The 290 determined data of this study reveal that nozzle A is identical in design and performance to the 291 primary for PIPAC developed predecessor, i.e., the microinjection pump MIP [8], which was 292 293 also distributed under the tradename CapnoPen.

Nozzle B (HurriChemTM) is another launched nebulizer for PIPAC. Examinations on design 294 295 and principle of operation show a high similarity with nozzle A (Nebulizer) and thus also with the initial PIPAC nozzle technology. At the manufacturer-recommended operational liquid flow 296 rate of 0.5 ml/s, nozzle B shows after an initiation time of 100 s an operational pressure of 297

All rights reserved. No reuse allowed without permission.

Göhler et al. Final 14.03.2023

298 14.9 bar. The mass median diameter of the droplets in the formed full spray jet cone (73°) was 299 determined to be 21 μ m.

Nozzle C (MCR-4 TOPOL[®]) differs in technical design, principle of operation, operational parameter and aerosol characteristics significantly from all other investigated nozzles. The operation of nozzle C is accompanied by the formation of a hollow spray cone jet (79°). At the manufacturer-recommended operational liquid flow rate range of (1.3 - 2.0) ml/s, operational pressures of (7.4 - 18.1) bar were reached within short initiation times of (18 - 26) s. The mass median droplet size decreases with increasing liquid flow rate, but was found to be in each case larger than 50 µm.

307 Nozzle D (QuattroJet) is a further PIPAC nebulizing nozzle that was introduced by the manufacturer of nozzle A. To optimize the spatial drug distribution pattern and higher 308 309 intraabdominal aerosol particle concentration, the conventional axial nozzle is supplemented in nozzle D by three further nozzles, which are arranged lateral at the nozzle head with an angular 310 distance of 120°. Nozzle D is based on the same technology as nozzle A. At the manufacturer-311 recommended flow rate of 1.5 ml/s, nozzle D shows an operational pressure of 16.0 bar after 312 an initiation time of 92 s and provides four full spray cone jets (67°) composed of droplets with 313 a mass median diameter of 21 µm. 314

Recently, a first attempt regarding recommendations on the minimum technical requirements 315 on nozzles suitable for PIPAC treatment was published. A minimum requirement for the spray 316 angle of at least 70° was defined [12] by implying that the spray cone angle corresponds to the 317 318 achievable drug deposition area. But there are two limitations found in this study that contradict this requirement. The present study shows that the requirement is matched directly by nozzle 319 A, B and C. But despite of a slightly lower spray cone angle of 67° than required, nozzle D 320 consists of four spatially-displaced spray jets cumulating in a total spray angle of 268°. On the 321 other hand, Nozzle C, unlike all other nozzles examined, had a hollow spray cone, resulting in 322 a ring-shaped drug deposition area that was smaller than that of a full spray cone jet at the same 323 spray cone angle. With regard on the nozzle performance, the drug deposition area seems to be 324 an even better technical parameter than the spray cone angle. 325

The examined nozzles C (MCR-4 TOPOL[®]) and D (QuattroJet) of this study show in contrast to A (Nebulizer) and B (HurriChemTM) and thus in contrast to the primary PIPAC nozzle technology significant differences in their principle of operation and performance. Nozzle C

Göhler et al. Final 14.03.2023

329 offers the largest spray cone angle of all examined nozzles, but also a hollow spray cone. It is not evident if such a spray jet improves drug distribution and drug penetration, since so far as 330 331 known there are no preclinical studies comparing a hollow with a full spray cone. Nozzle D provides multiple spray cones that can significantly improve the spatial drug distribution by 332 333 reduction of high local deposition and thus high local tissue toxicity. Nonetheless, these potential benefits of multi-nozzle systems need to be confirmed by further research. 334

A worrying result of this study was, that nozzle C (MCR-4 TOPOL[®]) shows in contrast to the 335 other nozzles a macroscopically visible formation of iron oxide after long-term exposure in a 336 sodium chloride containing cytostatic solution. Based on spark optical emission spectrometry, 337 it was found that this nozzle was made from a steel that, in addition to a 12-fold higher sulphur 338 content (0.012 wt.-% vs. 0.001 wt.-%), also contained amounts of molybdenum (0.183 wt.-%), 339 copper (0.220 wt.-%) and tungsten (0.134 wt.-%). Short-term exposure of the nebulizers to 340 cytostatic solution shows no immediate corrosion, but a possible risk for the patient cannot be 341 completely ruled out. This leads to the conclusion that manufacturer and regulatory authorities 342 for medical devices accreditation must also critically assess the suitability of specific steel 343 alloys for the administration of cytostatic drugs in their risk assessment. 344

Currently, there are only limited preclinical data to suggest that there is an optimal technique 345 for the generation and delivery of PIPAC aerosols that could improve clinical outcome. 346 However, it is clear that, contrary to claims made by one manufacturer [13], larger aerosol 347 droplets injected into the peritoneal cavity at higher velocities with a hollow spray cone do not 348 improve either the spatial distribution pattern [8, 14] or tissue penetration depth per se. 349 350 Nebulizers differing from the present standard technology in its design, especially in its 351 spraying characteristics, cannot automatically be considered equivalent by the clinical user. Therefore, before their broad clinical use, the individual innovation phases should be 352 353 systematically tested, ideally following the recommendation of the IDEAL-D framework for the introduction of medical devices [15, 16]. While the original nozzle technology has 354 completed phase I - IIb [17] and phase III trials are ongoing [4, 5], only limited phase I clinical 355 user data has been published for nozzle C (MCR-4 Topol[®]) [18]. Such data are lacking for 356 nozzle B and D. 357

In the near future, clinical users should be able to rely on technical testing and reporting being 358 based on scientific standards and generally applicable global standards, such as ISO standards. 359 For PIPAC nebulizers, such standards should ideally be set by a panel of experts through 360

Göhler et al. Final 14.03.2023

consensus conferences. Moreover, nebulizers with significant technical and granulometric 361 differences from the standard technology should undergo first ex- and in-vivo animal testing 362 363 before their first clinical use. Manufacturers should be obliged to have the bioequivalence of the cytostatic drugs administered independently certified in comparison to standard nebulizer 364 systems, analogous to drugs and their generics. Relevant outcome measures are aerosol 365 characteristics, spatial drug distribution, depth of penetration, tissue concentration and the peak 366 367 concentration and the area under the curve describing the extent of peritoneal passage [8, 19] -28]. The ratio between the individual properties of the generic nebulizer and the reference 368 product would ideally be 1:1 in case of bioequivalence. Since this is unlikely to be achieved, 369 the US Food and Drug Administration (FDA), for example, requires that the 90% confidence 370 interval should be between 0.80 and 1.25 [29]. Similar to the FDA specifications, new PIPAC 371 nozzle technologies could be tested comparatively in the future. Such preclinical testing, ideally 372 using standardized models, could prevent the use of such devices from compromising clinical 373 outcomes and/or harming healthcare professionals/patients. Finally, it would be helpful for the 374 comparability of clinical results if the nebulizer type used in each case will be also recorded in 375 the PIPAC database (https://isspp.org/professionals/pipac-database/). 376

377

5 Conclusion 378

Four clinically-used nozzles to aerosolise chemotherapeutic drugs in the context of Pressurized 379 Intraperitoneal Aerosol Chemotherapy (PIPAC), i.e., the Nebulizer, the HurriChemTM, the 380 MCR-4 TOPOL® and the QuattroJet were examined comparative to determine their 381 performance. 382

It could be confirmed that the Nebulizer shows quasi an identical technical design and thus also 383 a similar performance as the original PIPAC nozzles MIP/CapnoPen. The PIPAC nozzle 384 HurriChemTM is based on a similar technical design as the Nebulizer nozzle, but provides a 385 finer aerosol due to a smaller nozzle orifice opening. Both, the MCR-4 TOPOL® and the 386 QuattroJet deviate in the principles of operations to that of the Nebulizer and thus to the original 387 PIPAC technology. While the MCR-4 TOPOL[®] provides the coarsest aerosol of all examined 388 nozzles, the QuattroJet delivers an aerosol similar to that of the HurriChemTM. In contrast to the 389 HurriChemTM, the QuattroJet[®] comes with the feature of four spray cones (one axial, three 390 lateral) to improve the spatial drug distribution and a higher aerosol particle number 391 concentration. 392

Göhler et al. Final 14.03.2023

393 The availability of new PIPAC nozzles with special features is encouraging, but can also have a negative impact for establishment of the promising PIPAC approach for the treatment of 394 395 peritoneal carcinomatosis, if their performance and efficacy is unknown. It is therefore recommended that nozzles for which the technical/granulometric characteristics differ from the 396 current standard technology must be subjected to preclinical proof of equivalence in terms of 397 spatial drug distribution, tissue penetration and concentration before routine clinical use. It is 398 399 expected that representative in-silico models like the ones used in [23, 24] will be available in the near future. New nebulizers should be investigated and introduced for clinical use in 400 accordance with the IDEAL-D framework. 401

Göhler et al. Final 14.03.2023

403 **References**

- Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA Description of a novel approach for intraperitoneal drug delivery and the related device. Surg. Endosc. 2012;26(7):1849–1855. Doi: 10.1007/s00464-012-2148-0.
- 407 2. Solaß W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal
 408 carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence
 409 for efficacy. Ann. Surg. Oncol. 2014;21(2):553–559. Doi: 10.1245/s10434-013-3213-1.
- Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy:
 rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–e377. Doi:
 10.1016/S1470-2045(19)30318-3
- 4. Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC Pressurized IntraPeritoneal Aerosol
 Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases
 secondary to platinum resistant ovarian cancer study protocol for a randomized control
 trial. Pleura and Peritoneum 2019;4(1). Doi: 10.1515/pp-2018-0111
- 417 5. Casella F, Bencivenga M, Rosati R, et al. Pressurized intraperitoneal aerosol chemotherapy
 418 (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer:
 419 a randomized multicenter phase III trial PIPAC VEROne. Pleura and Peritoneum
 420 2022;7(3):135–141. Doi: 10.1515/pp-2022-0111
- 421 6. Sgarbura O, Villeneuve L, Alyami M, et al. Current practice of pressurized intraperitoneal
 422 aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?
 423 European Journal of Surgical Oncology 2021;47(1):149–156. Doi:
 424 10.1016/j.ejso.2020.08.020
- 425 7. Sgarbura O, Eveno C, Alyami M, et al. Consensus statement for treatment protocols in
 426 pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura and Peritoneum
 427 2022;7(1):1–7. Doi: 10.1515/pp-2022-0102
- 428 8. Göhler D, Khosrawipour V, Khosrawipour T, et al. Technical description of the micro 429 injection pump (MIP[®]) and granulometric characterization of the aerosol applied for 430 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Surg. Endosc. 431 2017;31(4):1778–1784. Doi: 10.1007/s00464-016-5174-5
- 432 9. Nadiradze G, Horvath P, Sautkin Y, et al. Overcoming Drug Resistance by Taking
 433 Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy
 434 (PIPAC). Cancers 2020;12(1):34. Doi: 10.3390/cancers12010034.

rights reserved. No reuse allowed without permissi Göhler et al. Final 14.03.2023

- 435 10. Arias GR, Sindayigaya R, Ouaissi M, et al. Safety and Feasibility of High-Pressure/High-
- 436 Dose Pressurized Intraperitoneal Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and
- 437 Metastatic Peritoneal Surface Malignancies. Ann. Surg. Oncol. 2022. Doi: 10.1245/s10434438 022-12698-4.
- 11. EN 10088-3:2014. Stainless steels Part 3: Technical delivery conditions for semi-finished
 products, bars, rods, wire, sections and bright products of corrosion resisting steels for
 general purpose.
- 442 12. Pocard M, So JBY, Huchon C, et al. PIPAC nebulizer: How to test the new devices in the
 443 market, expert recommendations. Journal of Visceral Surgery 2022. Doi:
 444 10.1016/j.jviscsurg.2022.10.001.
- 13. PIPAC Pressurized Intraperitoneal Aerosol Chemotherapy; https://www.skala.cz/en/mcr446 4-topol-en/ (access: 5th March 2023 at 11:02 CET)
- 14. Hinds, William C. (1999). Aerosol technology: properties, behaviour, and measurement of
 airborne particles. New York: Wiley. ISBN 978-0-471-19410-1.
- 15. Sedrakyan A, Campbell B, Merino JG, Kuntz R, Hirst A, McCulloch P IDEAL-D: a rational
 framework for evaluating and regulating the use of medical devices. Br. Med. J. 2016;i2372.
 Doi: 10.1136/bmj.i2372.
- 452 16. Páez A, Rovers M, Hutchison K, Rogers W, Vasey B, McCulloch P Beyond the RCT: When
 453 are Randomized Trials Unnecessary for New Therapeutic Devices, and What Should We
 454 Do Instead? Ann. Surg. 2021;275(2):324–331. Doi: 10.1097/SLA.00000000005053.
- 455 17. Baggaley AE, Lafaurie GBRC, Tate SJ, et al. Pressurized intraperitoneal aerosol
 456 chemotherapy (PIPAC): updated systematic review using the IDEAL framework. Br. J.
 457 Surg. 2022;110(1):10–18. Doi: 10.1093/bjs/znac284.
- 458 18. Hoskovec D, Dytrych P, Vocka M, Krska Z, Skala R MCR-4 TOPOL[®] new device for
 459 PIPAC first clinical use. Eur. J. Surg. Oncol. 2022;48(2):e155. Doi:
 460 10.1016/j.ejso.2021.12.308.
- 19. Rahimi-Gorji M, Debbaut C, Ghorbaniasl G, Cosyns S, Willaert W, Ceelen W Optimization
 of Intraperitoneal Aerosolized Drug Delivery: A Computational Fluid Dynamics (CFD) and
 Experimental Study. Scientific Reports 2021;12(1). Doi: 10.1038/s41598-022-10369-8.
- 464 20. Göhler D, Geldner A, Gritzki R, et al. Development of a rat capnoperitoneum phantom
 465 (RCP) to study drug aerosol deposition in the context of anticancer research on peritoneal
 466 carcinomatosis. Sci. Rep. 2021;11:21843. Doi: 10.1038/s41598-021-01332-0.

Göhler et al. Final 14.03.2023

- 21. Göhler D, Große S, Bellendorf A, et al. Hyperthermic intracavitary nano-aerosol therapy 467 (HINAT) as improved approach for pressurised intraperitoneal aerosol chemotherapy 468 469 (PIPAC): Technical description, experimental validation and first proof of concept.
- Beilstein J. Nanotechnol. 2017;8:2729–2740. Doi: 10.3762/bjnano.8.272. 470
- 471 22. Buggisch JR, Göhler D, Sobilo J, et al. Development and technical validation of an ultrasound nebulizer to deliver intraperitoneal pressurized aerosols in a rat colon cancer 472 473 peritoneal metastases model. BMC Cancer 2022;22(570). Doi: 10.1186/s12885-022-09668-
- 0. 474
- 23. Rezniczek GA, Buggisch J, Sobilo J, et al. Establishment of a mouse ovarian cancer and 475 peritoneal metastasis model to study intraperitoneal chemotherapy. Cancers 2020;12(12). 476 Doi: 10.3390/cancers12123818. 477
- 24. Höltzcke P, Sautkin I, Clere S, Castagna A, Königsrainer A, Pott PP, Reymond MA. 478 Feasibility of pressurized intra peritoneal aerosol chemotherapy using an ultrasound aerosol 479 generator (usPIPAC). Surg Endosc. 2022 Oct;36(10):7848-7858. doi: 10.1007/s00464-022-480 09525-y. Epub 2022 Aug 29. PMID: 36038646; PMCID: PMC9485099. 481
- 25. Toussaint L, Sautkin Y, Illing B, Weinreich FJ, Nadiradze G, Königsrainer A, Wichmann 482 D. Correction to: Comparison between microcatheter and nebulizer for generating 483 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Surg Endosc. 2021 484 Aug;35(8):4901. doi: 10.1007/s00464-021-08577-w. Erratum for: Surg Endosc. 2021 485 486 Apr;35(4):1636-1643. PMID: 34106308; PMCID: PMC8263410.
- 26. Mun J, Park SJ, Kim HS. Rotational intraperitoneal pressurized aerosol chemotherapy in a 487 488 porcine model. Gland Surg. 2021 Mar;10(3):1271-1275. doi: 10.21037/gs-2019-ursoc-11. PMID: 33842275; PMCID: PMC8033043. 489
- 27. Mimouni, M., Richard, C., Adenot, P. et al. Pressurized intra-peritoneal aerosol 490 chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution 491 492 patterns but leads to deeper penetration depth of doxorubicin in a sheep model. BMC Cancer 21, 461 (2021). https://doi.org/10.1186/s12885-021-07955-w 493
- 28. Giger-Pabst, U., Bucur, P., Roger, S. et al. Comparison of Tissue and Blood Concentrations 494 of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann 495 Surg Oncol 26, 4445–4451 (2019). https://doi.org/10.1245/s10434-019-07695-z 496

Göhler et al. Final 14.03.2023

- 29. Andrade C Bioequivalence of Generic Drugs: A Simple Explanation for a US Food and 498
- Drug Administration Requirement. Journal of Clinical Psychiatry 2015;76(06):e742-e744. 499
- Doi: 10.4088/JCP.15f10094. 500